Arrowhead Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2834 http://arrowheadpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics - May 26th, 2022 11:30 am
ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway… - May 16th, 2022 1:25 pm
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results - May 10th, 2022 8:00 pm
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives - May 9th, 2022 2:30 pm
Could The Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ownership Structure Tell Us Something Useful? - May 2nd, 2022 12:10 pm
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors - May 2nd, 2022 11:31 am
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences - May 2nd, 2022 11:30 am
Arrowhead Pharmaceuticals to Host Pulmonary R&D Day - Apr 27th, 2022 11:30 am
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia - Apr 26th, 2022 11:30 am
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market - Apr 25th, 2022 11:30 am
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results - Apr 20th, 2022 8:00 pm
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Apr 6th, 2022 11:30 am
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences - Apr 1st, 2022 11:30 am
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases - Mar 24th, 2022 11:30 am
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma - Mar 15th, 2022 11:30 am
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia - Feb 24th, 2022 12:30 pm
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases - Feb 18th, 2022 12:30 pm
Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022 - Feb 17th, 2022 12:30 pm
The Best Russell 2000 Stocks to Buy Before they Rebound - Feb 15th, 2022 8:06 pm
ARWR: New Pulmonary Programs Announced… - Feb 9th, 2022 1:25 pm